[Cytostatic immunosuppressive therapy, chromosomal aberrations and carcinogenic effect (author's transl)].
D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001379:Azathioprine / Q000009:adverse effects / Q000627:therapeutic use; D002869:Chromosome Aberrations; D002900:Chromosomes, Human, 1-3; D002901:Chromosomes, Human, 13-15; D002902:Chromosomes, Human, 16-18; D002903:Chromosomes, Human, 19-20; D002904:Chromosomes, Human, 21-22 and Y; D002905:Chromosomes, Human, 4-5; D002906:Chromosomes, Human, 6-12 and X; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008297:Male; D008357:Mannomustine / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D009374:Neoplasms, Experimental / Q000139:chemically induced*; D011344:Procarbazine / Q000009:adverse effects / Q000627:therapeutic use; D012730:Sex Chromosomes; D014178:Translocation, Genetic
D007166:Immunosuppressive Agents; D011344:Procarbazine; D003520:Cyclophosphamide; D008357:Mannomustine; D001379:Azathioprine
Zytostatische immunodepressive Therapie, chromosomale Aberrationen und karzinogene Wirkung